Get Live Data

Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.

Less Ads, More Data, More Tools Register for FREE
Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada
Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in CanadaView Video
Roundtable Discussion; The Future of Mineral Sands
Roundtable Discussion; The Future of Mineral SandsView Video

Latest Share Chat

  2. Share Prices
  3. Avacta Group Share Price
  4. Avacta Group Share News
  5. IN BRIEF: Avacta Stock Continues Rise After Launch Of SARS-CoV-2 Test

Pin to quick picksAvacta Group Share News (AVCT)

Avacta Group Information

Share Price Information for Avacta Group (AVCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 45.75
Bid: 45.50
Ask: 46.00
Change: 1.00 (2.19%)
Spread: 0.50 (1.099%)
Open: 45.00
High: 46.75
Low: 44.25
Prev. Close: 45.75
AVCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

IN BRIEF: Avacta Stock Continues Rise After Launch Of SARS-CoV-2 Test

Thu, 01st Oct 2020 06:40

Avacta Group PLC - Wetherby, England-based pre-clinical stage biotechnology company - Launches bead-assisted mass spectrometry, or BAMS, SARS-CoV-2 virus test. "The BAMS assay uses the Affimer reagents specific to the SARS-CoV-2 virus to capture the virus spike protein from the sample for rapid detection by mass spectrometry, using the installed base of these instruments in hospitals," Avacta says. Adds that one thousand samples per day can be analysed by a single technician using BAMS.

Current stock price: 155.00 pence, up 11% on Wednesday.

Year-to-date change: up sharply from 17.25p

By Eric Cunha; ericcunha@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
8 Mar 2021 11:06

Avacta confirms efficacy of test on variant Covid-19 strains

(Sharecast News) - Cancer therapies and diagnostics company Avacta announced on Monday that its 'AffiDX' SARS-CoV-2 rapid antigen lateral flow test detected the dominant new variants of coronavirus, known as the B117 or 'Kent', variant, and the D614G variant, as well as the original strain.

Read more
24 Feb 2021 11:45

TRADING UPDATES: Avacta Plans Covid Test Launch Near First Quarter End

TRADING UPDATES: Avacta Plans Covid Test Launch Near First Quarter End

Read more
24 Feb 2021 10:25

AIM WINNERS & LOSERS: Mkango Hails Pilot Plant Processing Milestone

AIM WINNERS & LOSERS: Mkango Hails Pilot Plant Processing Milestone

Read more
22 Feb 2021 11:01

AIM WINNERS & LOSERS: Clear Leisure Surges Amid Placing, Bitcoin Plans

AIM WINNERS & LOSERS: Clear Leisure Surges Amid Placing, Bitcoin Plans

Read more
22 Feb 2021 09:28

Avacta Focusing On Full Clinical Validation Of Rapid Covid-19 Test

Avacta Focusing On Full Clinical Validation Of Rapid Covid-19 Test

Read more
22 Feb 2021 08:54

Avacta clarifies reports on potential use of its Covid-19 test

(Sharecast News) - Avacta Group responded to some press speculation on take-up of its lateral flow SARS-CoV-2 rapid antigen test for Covid-19 by the UK government on Monday.

Read more
22 Feb 2021 08:47

LONDON MARKET OPEN: European Equities Slip Amid Inflation Fears

LONDON MARKET OPEN: European Equities Slip Amid Inflation Fears

Read more
18 Feb 2021 14:31

IN BRIEF: Avacta Gets Phase I Clinical Trial Approval For AVA6000

IN BRIEF: Avacta Gets Phase I Clinical Trial Approval For AVA6000

Read more
18 Feb 2021 08:49

Avacta gets approval for first-in-human study of AVA6000

(Sharecast News) - Biotherapeutics and reagents developer Avacta has received approval from the Medicines and Healthcare Products Regulatory Agency (MHRA) for a phase 1 study of its lead 'preCISION' pro-drug, AVA6000 pro-doxorubicin, it announced on Thursday.

Read more
16 Feb 2021 11:31

AIM WINNERS & LOSERS: Cornish Metals Jumps 40% On AIM Debut

AIM WINNERS & LOSERS: Cornish Metals Jumps 40% On AIM Debut

Read more
16 Feb 2021 09:48

Avacta Shares Surge On Positive Data For Covid-19 Antigen Test

Avacta Shares Surge On Positive Data For Covid-19 Antigen Test

Read more
16 Feb 2021 09:38

Avacta upbeat on initial data for Covid-19 rapid test study

(Sharecast News) - Biotherapeutics and reagents developer Avacta Group has received the first data for its SARS-CoV-2 rapid antigen test from ongoing clinical studies in Europe and the UK, it announced on Tuesday.

Read more
8 Feb 2021 11:25

Avacta enters commercial partnership with Mologic

(Sharecast News) - Biotherapeutics developer Avacta Group has entered into a commercial partnership with Mologic, it announced on Monday, to accelerate to market its 'AffiDX' SARS-CoV-2 lateral flow rapid antigen test.

Read more
8 Feb 2021 10:46

AIM WINNERS & LOSERS: Bahamas Petroleum Sinks As Pulls Plug On Well

AIM WINNERS & LOSERS: Bahamas Petroleum Sinks As Pulls Plug On Well

Read more
8 Feb 2021 09:37

Avacta Signs Agreement With Mologic For AffiDX Covid-19 Antigen Test

Avacta Signs Agreement With Mologic For AffiDX Covid-19 Antigen Test

Read more
67891011121314

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.